Dbv Technologies
France corporation · 1 known investors
DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy treatments, primarily the VIASKIN patch, for food allergies and immunological diseases. The company focuses on treating peanut allergy, cow's milk allergy, and related conditions in pediatric and adult patients.
Founders & leadership
PM
Pharis MohideenExecutive Officer
DT
Daniel TasseExecutive Officer, Director
VB
Virginie BoucinhaExecutive Officer
U(
Unknown (founded by pediatricians)
MF
Mailys FerrereDirector
MG
Michael GollerDirector
RM
Ravi Madduri RaoDirector
DG
Daniele Guyot-CaparrosDirector
DS
Daniel SolandDirector
AN
Adora NduDirector
JO
Julie O'NeillDirector
MD
Michel de RosenDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$306.9MraisedApr 2025 · 14 investors · PharmaceuticalsRule 506(b)
▶$306.9MraisedApr 2025 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mailys FerrereDirector
- Ravi Madduri RaoDirector
- Daniele Guyot-CaparrosDirector
- Pharis MohideenExecutive Officer
- Daniel SolandDirector
- Adora NduDirector
- Julie O'NeillDirector
- Daniel TasseExecutive Officer, Director
- Virginie BoucinhaExecutive Officer
- Michel de RosenDirector
- Timothy E. MorrisDirector
- Michael GollerDirector
- Offering amount
- $306.9M
- Amount sold
- $306.9M
- Sales commissions
- $18.4M
- Placement agents
- Van Lanschot Kempen NV, Van Lanschot Kempen (USA) Inc., LifeSci Capital LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, France
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.